Clinical trials: Hidradenitis
Hidradenitis Suppurativa
Real-world Secukinumab Outcomes in Canadian HS Patients
The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab…
- Trial name
- HS-RISE (NCT07282015)
- Where
- 15 sites in Canada
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa (HS)
Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects
The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.
- Trial name
- HS rPMS (NCT03001115)
- Where
- 19 sites in South Korea
- Volunteers
- 17 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
- Trial name
- NCT07049575
- Testing
- Ruxolitinib Cream
- Where
- 21 sites in United States
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo controlled period, followed by a 42-week…
- Trial name
- STOP-HS1 (NCT05620823)
- Testing
- Povorcitinib
- Where
- 104 sites in United States, Austria and 10 more
- Volunteers
- 608 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (Acne Inversa)
Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients
This is a randomized, double blind, multicenter study in patients with moderate to severe chronic hidradenitis suppurativa in parallel groups, to determine the efficacy and safety of multiple doses of CJM112 in comparison to…
- Trial name
- NCT02421172
- Testing
- CJM112
- Where
- 16 sites in United States, Denmark and 3 more
- Volunteers
- 66 people
- Sponsor
- Novartis Pharmaceuticals
Skin Lesions, Melanocytic Nevi
Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.
This study aims to determine if an artificial intelligence (AI) medical device can help primary care doctors more accurately identify and manage various skin conditions.
- Conditions
- Skin Lesions, Melanocytic Nevi, Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
- Trial name
- LegitHealth PH (NCT07428941)
- Testing
- AI-based medical device for aided diagnosis in dermatological conditions
- Where
- Spain
- Volunteers
- 9 people
- Sponsor
- AI Labs Group S.L
Hidradenitis Suppurativa (HS)
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
- Trial name
- NCT07213973
- Testing
- Povorcitinib
- Where
- 30 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa
Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa
The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER (OLE) (NCT01635764)
- Testing
- adalimumab
- Volunteers
- 508 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
- Trial name
- NCT06959225
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 101 sites in United States, Bulgaria and 6 more
- Volunteers
- 580 people
- Sponsor
- Incyte Corporation
Hidradenitis Suppurativa (HS)
Short-term Treatment Satisfaction in Hidradenitis Suppurativa Patients Initiated on Cosentyx in Routine Clinical Practice in Saudi Arabia
This study aims to assess the treatment satisfaction of HS patients newly started on secukinumab in Saudi Arabia, in terms of patient reported convenience, perceived safety, perceived effectiveness and global treatment…
- Trial name
- ILLUMINATE-SA (NCT06785779)
- Testing
- Secukinmab
- Where
- 4 sites in Saudi Arabia
- Volunteers
- 77 people
- Sponsor
- Novartis Pharmaceuticals
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab in adult participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- NOVA (NCT03628924)
- Testing
- Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3
- Where
- 45 sites in United States, Canada and 4 more
- Volunteers
- 184 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to evaluate the clinical efficacy of bermekimab in participants with moderate to severe Hidradenitis Suppurativa (HS).
- Trial name
- LYRA (NCT04988308)
- Testing
- Bermekimab, Adalimumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 151 people
- Sponsor
- Janssen Research & Development, LLC
Herpes Genitalis, Genital Wart
Safety and Efficacy of Laser Therapy in Gynaecology
The aim of this study is to retrospectively evaluate the effectiveness and safety of Er:YAG laser for treatment of different gynecological indication, e.g.
- Conditions
- Herpes Genitalis, Genital Wart, Lichen Sclerosus, Cervical Intraepithelial Neoplasia
- Trial name
- NCT04073082
- Where
- Slovenia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Juna d.o.o.
Hidradenitis Suppurativa
A Journey Into Participation Patterns Among Patients With Hidradenitis Suppurativa
This study aims to uncover the factors driving patient decisions regarding enrollment, withdrawal, or re-engagement in hidradenitis suppurativa clinical trials.
- Trial name
- NCT06201858
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Hidradenitis Suppurativa
A Study of Bermekimab in Patients With Hidradenitis Suppurativa
Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.
- Trial name
- NCT03512275
- Testing
- Bermekimab Monoclonal Antibody 400 mg
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Janssen Research & Development, LLC
Hidradenitis Suppurativa (HS)
A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab
This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or study 1368-0100).
- Trial name
- NCT06241573
- Testing
- Spesolimab
- Where
- 36 sites in United States, Argentina and 12 more
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER I (NCT01468207)
- Testing
- adalimumab
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin…
- Trial name
- Intrepid (NCT06468228)
- Testing
- Lutikizumab
- Where
- 279 sites in United States, Argentina and 42 more
- Volunteers
- 1,400 people
- Sponsor
- AbbVie
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
- Trial name
- NCT06411379
- Testing
- Sonelokimab
- Where
- 106 sites in United States, Belgium and 10 more
- Volunteers
- 418 people
- Sponsor
- MoonLake Immunotherapeutics AG
Chronic Urticaria, Idiopathic, Hidradenitis
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days.
- Conditions
- Chronic Urticaria, Idiopathic, Hidradenitis, Hidradenitis Suppurativa
- Trial name
- NCT06555328
- Testing
- CSU lower dose treatment, CSU high dose treatment, CSU non responders IgE - high dose treatment
- Where
- 29 sites in United States, Bulgaria and 4 more
- Volunteers
- 73 people
- Sponsor
- InflaRx GmbH